San Francisco - June 22, 2020. Silverberry Genomix, a leading company in digital health based in San Francisco, announced the release of a new DNA-Based report to assess the impact risk of COVID-19.
Geneticists have turned up intriguing links between DNA and the COVID-19 disease. Some studies suggest that patients with certain types of genetic variation that is also known for predisposition to cognitive decline, seem to be at greater risk and may experience severe illness if infected by the Coronavirus 2 (SARS-CoV-2).
The new package, called “COVID-19 Impact Risk Report”, analyzes the genetic makeup to identify individuals at greater risk who may experience severe illness if infected by the virus.
To analyze the risk, Silverberry is using the regular DNA files produced by microarray and analyzes the SNPs reported in the files.
The new report is part of Silverberry Genomix’s response to the pandemic caused by the Coronavirus. The other activities include:
- Corona Expert: FAQ and most recent updates about the virus.
- COVID-19 Genomic Study.
- Safe Office: Services to safely reopen dental offices.
For more information about the new report and order, visit https://silverberrygenomix.
About Silverberry Genomix
Silverberry Genomix is a leading digital health platform that utilizes AI and machine learning to provide personalized assessments and recommendations to optimize health and wellness plans. By offering a DNA Testing Kit, anyone can take the test and receive a personalized assessment as well as a wide range of recommendations. Those with an existing DNA file may upload their file and get access to Comprehensive DNA Health Reports. For more information visit https://silverberrygenomics.com/